Impact of hemophilia on school, work, and leisure activities of patients assisted at the Hemocentro Regional de Montes Claros/Minas Gerais
DOI:
https://doi.org/10.33448/rsd-v11i13.35661Keywords:
Hemophilia; Prophylaxis; Quality of life.Abstract
Hemophilias are bleeding diseases determined by the deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). This study aimed to analyze the impact of hemophilia on the school, work, and leisure activities of patients seen at the Hemocentro Regional de Montes Claros/MG. This is a cross-sectional, descriptive, quanti-qualitative study, based on interviews and data from medical records. The data were submitted for statistical analysis. Participated in the research 22/43 male subjects, over 18 years old, with hemophilia. Age ranged from 20 to 54 years. The majority (10/22) presented the moderate form and 4/22 the severe form. One participant had a high-titer inhibitor. There was a prevalence of incomplete high school education (5/22), paid activity (12/22), and retired (8/22). The reported income was 1 minimum wage for 40.9%. The main complications recorded were hemarthrosis (17/22), mainly in the knees and elbows. In the group, 40.9% perform regular physical activity and the most frequent leisure activities were watching movies, TV, computer, and online games. Most were single (68.2%) and those who had children corresponded to 36.4%. Discussion: Hemorrhagic events in hemophilia worsen the quality of life. In this study, 36.4% participate in the secondary/ tertiary prophylaxis program with factor VIII or IX. Early initiation of primary prophylaxis (Ministry of Health, 2015) and patient compliance, allow promising results, particularly in reducing degenerative arthropathies, often disabling (Bezerra, 2022). It is concluded that hemophilia interferes with school, work, and leisure activities, and prophylaxis programs, DDU, and access to multiprofessional care are determinants for a better quality of life for these patients.
References
Batorova, A., Jankovicova, D., Morongova, A., Bubanska, E., Prigancova, T., Horakova, J., et al. (2016). Inhibitors in severe hemophilia A: 25-year experience in Slovakia. Paper presented at the Seminars in Thrombosis and Hemostasis.
Bezerra, J. R. P., da Silva Tiago, A. C., da Silva Quintal, J., Buriti, M. A., Buriti, M. A., Ribeiro, C. H. M. A., et al. (2022). Relação entre adesão ao tratamento e qualidade de vida na hemofilia: revisão integrativa da literatura. Research, Society and Development, 11(11), e448111130318-e448111130318.
Brasil. (2014). Anvisa. RESOLUÇÃO - RDC N° 34, DE 11 DE JUNHO DE 2014.
Brasil. (2017). Ministério da Saúde. Potaria de consolidação Nº5, anexo IV. Ministério da Saúde 2017.
Brasil. (2021). Ministério da Saúde. Protocolo de uso de Emicizumabe por pacientes com Hemofilia A e Inibidores do Fator VIII refratários ao tratamento de imunotolerância. Brasília: Ministério da saúde, 2021. https://www.gov.br/saude/pt-br/assuntos/pcdt/arquivos/2021/portal-portaria-conjuntano-15-pu-emicizumabe_hemofilia.pdf.
Brasil, M. d. S. (2008). Ministério da Saúde. Hemofilia congênita e inibidor: manual de diagnóstico e tratamento de eventos hemorrágicos. Brasília: Ministério da Saúde, 2008. https://bvsms.saude.gov.br/bvs/publicacoes/hemofilia_congenita_inibidor_diagnostico_tratamento.pdf. . Portaria MS.
Brasil, M. d. S. (2015). Ministério da Saúde, Manual de hemofilia. Brasília: Ministério da saúde, 2015. https://bvsms.saude.gov.br Portaria MS.
DeKoven, M., Karkare, S., Lee, W., Kelley, L., Cooper, D., Pham, H., et al. (2014). Impact of haemophilia with inhibitors on caregiver burden in the United States. Haemophilia, 20(6), 822-830.
Ewing, N., Escuriola‐Ettingshausen, C., & Kreuz, W. (2015). Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia, 21(3), 358-364.
Lai, J., Hough, C., Tarrant, J., & Lillicrap, D. (2017). Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood, The Journal of the American Society of Hematology, 129(24), 3147-3154.
Lai, J. D., Moorehead, P. C., Sponagle, K., Steinitz, K. N., Reipert, B. M., Hough, C., et al. (2016). Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A. Blood, The Journal of the American Society of Hematology, 127(26), 3439-3449.
Ljung, R., Auerswald, G., Benson, G., Dolan, G., Duffy, A., Hermans, C., et al. (2019). Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients. European journal of haematology, 102(2), 111-122.
Ljung, R. C. (2018). How I manage patients with inherited haemophilia A and B and factor inhibitors. British Journal of Haematology, 180(4), 501-510.
Lochan, A., Macaulay, S., Chen, W., Mahlangu, J., & Krause, A. (2014). Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia, 20(5), 687-692.
Martins, T. S., & Nóbrega, J. (2018). Segurança transfusional no Brasil: dos primórdios ao NAT. RBAC, 50(4), 321-326.
Miller, C. H., Rice, A. S., Boylan, B., Payne, A. B., Kelly, F. M., Escobar, M. A., et al. (2015). Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening. Am J Hematol, 90(10), 871-876.
Miller, C. H., Rice, A. S., Boylan, B., Payne, A. B., Kelly, F. M., Escobar, M. A., et al. (2015). Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening. American journal of hematology, 90(10), 871-876.
Minayo, M. C. d. S., Hartz, Z. M. d. A., & Buss, P. M. (2000). Qualidade de vida e saúde: um debate necessário. Ciência & saúde coletiva, 5, 7-18.
Naderi, N., Yousefi, H., Mollazadeh, S., Seyed Mikaeili, A., Keshavarz Norouzpour, M., Jazebi, M., et al. (2019). Inflammatory and immune response genes: a genetic analysis of inhibitor development in Iranian hemophilia A patients. Pediatric Hematology and Oncology, 36(1), 28-39.
Nunes, A. A., Rodrigues, B. S., Soares, E. M., Soares, S., & Miranzi, S. S. (2009). Qualidade de vida de pacientes hemofílicos acompanhados em ambulatório de hematologia. Revista Brasileira de Hematologia e Hemoterapia, 31, 437-443.
Oldenburg, J., Kulkarni, R., Srivastava, A., Mahlangu, J., Blanchette, V., Tsao, E., et al. (2018). Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia, 24(1), 77-84.
Pinto, G. F. A. (2015). Respostas funcionais e eletromiográficas em pacientes com hemofilia submetidos a atividades aquáticas funcionais. Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas.
Pio, S. F., Oliveira, G. C. D., & Rezende, S. M. (2009). As bases moleculares da hemofilia A. Revista da Associação Médica Brasileira, 55, 213-219.
Ranal, D. (2014). Hemofilia: tratamento e profilaxia.
Teles, W. S., Silva, M. H. S., Torres, R. C., Debbo, A., Costa, M. F., Silva, R. N., ... & Silva, M. C. (2021). Perfil epidemiológico dos hemofílicos em tratamento em um ambulatório do nosdeste brasileiro. Hematology, Transfusion and Cell Therapy, 43, S230.
Wyatt, K. D., Coon, L. M., Rusk, D. N., Rodriguez, V., & Warad, D. M. (2019). Case Report: Development of Factor VIII Inhibitor in a Patient with an Uncommon de novo Mutation in the Factor VIII Gene. Acta Haematologica, 141(3), 129-134.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Arthur Macedo Goulart Silva; Alessa Assis Guimarães Silvério ; Leandro de Freitas Teles ; Larissa Caires Gonzaga ; José Wilson de Brito Sales; Tânia de Cássia Moreira Soares; Rafael Cândido Alves Aguiar; Elaine Veloso Rocha Urias
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
